Please assess the completion status of the following clinical trial:

Trial Title: Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant~2. Must have received first line chemotherapy. No upper limit to number of prior therapies~3. Evaluable Disease~4. Age \>18 years~5. Eastern Cooperative Oncology Group (ECOG) performance status \<2~6. Life expectancy of greater than 3 months~7. Patients must have adequate organ and marrow function~8. Adequate Contraception~9. Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~1. Prior Therapy~   * Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~  * Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs~  * No monoclonal antibody within 3 months unless evidence of progression~2. Patients may not be receiving any other investigational agents~3. Patients with known central nervous system metastases, including lymphomatous meningitis~4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide~5. Uncontrolled intercurrent illness~6. Pregnant women~7. Nursing women~8. Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years~9. Patient is known to be Human Immunodeficiency Virus (HIV)-positive~10. Active Hepatitis A, Hepatitis B, or Hepatitis C infection~11. Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V/N: Level 1 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
- V/N: Level 2 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
- V/N: Level 3 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
- V/N: Level 4 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
- V/N: Level 5 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
- V/N/E: Level 1 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
- V/N/E: Level 2 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
- V/N/E: Level 3 (Type: EXPERIMENTAL): Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete